pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›emraclidine
drug · small molecule
save

emraclidine

Phase 2updated 6mo ago
by $ABBV AbbVie Inc.🔗 ChEMBL
Phase 2
community read0 votes

Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying emraclidine

  • phase1Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteersrecruitingn=12
  • phase2A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophreniarecruitingn=268
  • phase1A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participantsrecruitingn=32
  • phase2A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophreniacompletedn=391
  • phase2A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophreniacompletedn=385
  • phase1A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Diseasecompletedn=17
  • phase1A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Functioncompletedn=58
  • phase1A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidinecompletedn=38

News(4)

  • Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
    Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for tr…
    biospace · 4d ago
  • With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
    After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squi…
    biospace · 8d ago
  • AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
    In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.
    biospace · 1mo ago
  • As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
    Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…
    biospace · 3mo ago
generic
emraclidine
indication
Psychosis
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?